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i 
Abstract 
Post-traumatic Osteoarthritis (PTOA) is a degenerative joint disease, leading to articular 
cartilage breakdown, osteophytes, and synovitis, caused by an initial joint trauma. Pro-
inflammatory cytokines increase catabolic activity and may perpetuate inflammation 
following joint trauma. Interleukin-15 (IL-15), a pro-inflammatory cytokine, is increased 
in OA patients, although its exact role in the disease pathology is unknown. Using Il15 
deficient rats, this study investigated the role of IL-15 in PTOA pathogenesis in an injury-
induced model of OA. Semi-quantitative scoring of the articular cartilage, subchondral 
bone, and osteophyte formation reveals no significant difference between Il15 deficient 
rats and wild-type rats, following PTOA-induction. Similarly, synovitis scoring across 6 
parameters found no significant difference between genetic variants. Overall, IL-15 does 
not appear to play a key role in PTOA pathogenesis in this model. 
Keywords: Interleukin-15, post-traumatic osteoarthritis, articular cartilage, synovial 
joint, transgenic rats  
ii 
Summary for Lay Audience 
Post-traumatic Osteoarthritis (PTOA) is a degenerative joint disease, leading to 
cartilage breakdown and changes to the surrounding tissue, caused by an initial joint 
injury. Pro-inflammatory cytokines may increase joint damage and cause chronic 
inflammation following joint trauma. Interluekin-15 (IL-15), a pro-inflammatory cytokine, 
is increased in OA patients, although its exact role in the disease is unknown. 
Using Il15 deficient rats, this study investigated the role of IL-15 in PTOA progression in 
an injury-induced model of OA. The cartilage, bone, and joint capsule were analyzed to 
assess PTOA damage. Examination of the joint tissue reveals no significant difference 
between Il15 deficient rats and control rats, following PTOA-induction. Overall, IL-15 




All data presented in this thesis was collected and analyzed by Ermina Hadzic. 
Dr. Stephen Renaud provided the initial Il15-/+ rats, which were bred in house and 
maintained by Ermina Hadzic. Garth Blacker performed all of the anterior cruciate 
ligament and destabilized medial meniscus (ACLT-DMM) surgeries to induce OA and 
assisted in semi-quantitative scoring. Holly Dupuis assisted in tissue collection and 
semi-quantitative scoring. Dr. Frank Beier contributed to the study design and editing of 





I have spent almost 7 years in the Beier lab, so there are many amazing people to 
acknowledge, the first of which is my supervisor, Dr. Frank Beier. Frank, thank you for 
taking the chance on me as a high school co-op student. Your support and 
encouragement has helped me grow both as a student and as a person. I have been 
able to challenge myself in my work, always knowing I had the support of you and the 
lab behind me. It has been a hard year for everyone, but you have faced some of the 
hardest challenges and continue to impress everyone with your strength. I could not 
think of a better mentor. I know that you will be able to handle anything that comes your 
way.  
To my advisory committee: Dr. Appleton, Dr. Renaud, and Dr. Tirona. Thank you for all 
of the feedback and time spent pushing me to be a better scientist. Your willingness to 
collaborate and spend the time working with me is greatly appreciated.  
 
The Beier lab is everchanging, but Dawn and Holly have been the constant that keep it 
running. Dawn, you are one of the smartest and kindest people I know. You are always 
there to patiently help me and offer words of encouragement. The lab would not be as 
welcoming, or safe for that matter, without you. Holly, I’m still not sure why you took me 
under your wing when I was just a co-op student, but I do know that I wouldn’t be where 
I am without you. While I do love to give you a hard time, you are a brilliant scientist and 
an incredibly kind-hearted person under all of the tough exterior. Thank you to Anusha, 
Margaret, Mike, Ayten, Kristyn, Bethia, the Brazilians (Melina & Manuela), Supinder, 
Carina, and all other Beier lab alumni who I don’t have the space to mention. I could 
always count on you to make the time to help me with any kind of experiment 
troubleshooting. You made coming into lab fun and I truly miss all of you. Thank you to 
our neighbouring Appleton and Séguin labs. Garth, thank you for taking the time to do 
all of my rat surgeries and all the help with the synovial scoring. Everyone has been 
incredibly collaborative and helpful, a testament to the leadership from Dr. Tom 
Appleton and Dr. Cheryle Séguin. A special thank you to Tom and Cheryle for stepping 
in and helping out our lab during Frank’s recovery.  
 v 
Finally, thank you to my friends and family for your continued love and support. Thank 
you to my parents, who worked hard to give my sister and I the best life and instilled in 
us the importance of education. Mom and Dad, you have ensured we have every 
opportunity available to us, and I am forever thankful. Armela, you are my polar 
opposite in every conceivable way, and I love every part of you. You have been one of 
my biggest supporters and I have always tried to mirror your work ethic. I miss you 
dearly. Belmin, thank you for taking care of Armela, I know she’s a handful. Ayleen, we 
can’t wait to meet you and love you so much already. Thank you to my extended family, 
especially Ismar and Irfan. You boys always make me laugh. Miki loves you. Thank you 
to my dear friends, who may as well be family at this point. You have kept me sane 




Table of Contents 
Abstract…………………………………………………………………………………….……..i 
Summary for Lay Audience…………………………………………………………………….ii 
Co-Authorship Statement………………………………………………………………….…..iii 
Acknowledgements…………………………………………………………………………..…iv 
Table of Contents…………………………………………………………………………….…vi 
List of Tables…………………………………………………………………………..……….viii 
List of Figures……………………………………………….………………………………..…ix 
List of Abbreviations…………………………….…………………………………...………….x  
Chapter 1: Introduction…………………………………………………………………………1 
1. Introduction……………………………………………………………...……………….2 
1.1 The Synovial Joint………………………………………………………………….2 
1.1.1 Articular Cartilage……………………………………………..…………….4 
1.1.2 Bone & Subchondral Bone………………………..………………………..7 
1.1.3 Synovium…………………………………………………………………….8 
1.1.4 Supporting Structures…………………………………..…………………10 
1.2 OA Pathophysiology……………………………………….……………………..11 
1.2.1 Articular Cartilage Effects……………………………..………………….11 
1.2.2 Subchondral Bone Effects……………………………..…………………13 
1.2.3 Synovitis……………………………………………………….……………14 
1.2.4 Supporting Structures Effects…………………………………………….15 
1.3 Risk Factors and Diagnosis………………………………………………..……16 
1.4 Pain……………………………………………………………….………………..17 
1.5 Treatment………………………………………………………….………………19 
1.6 Stratification of OA………………………………………………..………………21 
1.7 PTOA………………………………………………………...…………………….21 
1.8 Inflammation in OA……………………………………………………………….23 
1.9 Cytokines…………………………………………………………………………..24 
1.9.1 IL-15…………………………………………………………………………25 
1.10 Rationale, Hypothesis, Objectives………………………………….………..27 
1.10.1  Rationale……………………………………………..……………..……..27 
 vii 
1.10.2  Hypothesis…………………………………………………………………27 
1.10.3  Objectives…………………………………………………………...……..28 
Chapter 2: Materials & Methods………………………………………………..……………29 
 2.1  Animals and Genotyping…………………………………………………………30 
 2.2  Surgery…………………………………………………………………………….32 
 2.3  Behavioural Testing………………………………………………………….…..34 
 2.4  Histopathology and Scoring……………………………………………………..34 
 2.5  Statistical Analysis………………………………………………………………..38 
Chapter 3: Results……………………………………………………………………………..39 
 3.1  General Health and Behavioural Analysis………………………...…………...40 
 3.2  Control Group……………………………………………………………………..44 
 3.3  Cartilage Damage after Surgery………………...………………………….…..47 
 3.4  Subchondral Bone and Osteophytes…………………………………..……….51 
 3.5  Synovitis…………………………………………………………………….……..56 
Chapter 4: Discussion……………………………………………………..………………….60 
 4.1  Limitations and Future Directions………………………………….……………65 
Chapter 5: References……………………………………………………….……………….67 








List of Tables 
 




List of Figures 
 
Figure 1.1 The synovial joint in a healthy and osteoarthritic knee……...………………….3 
Figure 1.2 Articular cartilage is organized in distinct zones……………...…………………6  
Figure 2.1 Genetically modified Holtzmann-Sprague Dawley rats………...……………..31 
Figure 2.2 Surgically-induced OA……………………………………………………………33 
Figure 2.3 OARSI scoring methodology was used to assess OA………………………..36 
Figure 3.1 All groups gained weight at a similar rate over the 8 weeks…………………41 
Figure 3.2 Exploratory analyses of effects of PTOA on mechanical allodynia………….42 
Figure 3.3 Representative histological images demonstrate healthy joint tissue  
in Naive rats………………………………………………………………………………..…..45 
Figure 3.4 Sample image of tissue damage in Naive rats………………………………...46 
Figure 3.5 Cartilage damage is not significantly different between Il15+/+ PTOA and  
Il15-/- PTOA animals……………………………………………………………….…………..48 
Figure 3.6 Representative high magnitude images of articular cartilage damage……...49 
Figure 3.7 Representative histological images demonstrate greatest damage in  
the medial compartment of the PTOA group……………………………………………….50 
Figure 3.8 Subchondral bone damage is not significantly different between 
 Il15+/+ PTOA and Il15-/- PTOA rats…………………………………………………………..52 
Figure 3.9 Representative image of subchondral bone damage in PTOA rats…………53 
Figure 3.10 Osteophyte size is not significantly different between Il15+/+ and  
Il15-/- animals……………………………………………………………………………………54 
Figure 3.11 Synovitis is not significantly different between Il15+/+ and  
Il15-/- animals………………………………………………………………………………..….57 








List of Abbreviations 
 
ACL  Anterior Cruciate Ligament  
ACLT-DMM Anterior Cruciate Ligament Transection with Destabilized Medial Meniscus  
ADAMTS A Disintegrin and Metalloproteinase with Thrombospondin-like Motifs 
BMP  Bone Morphogenic Protein  
CNS  Central Nervous System 
DAMP  Damage Associated Molecular Patterns  
DMOAD Disease Modifying Osteoarthritis Drug   
ECM   Extracellular Matrix  
FLS  Fibrous-like Synoviocytes 
GAG  Glycosaminoglycan 
IACS  Intra-Articular Corticosteroid 
IAHA  Intra-Articular Hyaluronan  
IL  Interleukin  
KL  Kellgren-Lawrence  
LFC  Lateral Femoral Condyle  
LTP  Lateral Tibial Plateau  
MAC  Membrane Attack Complex  
MFC  Medial Femoral Condyle 
MLS  Macrophage-like Synoviocytes 
MMP  Matrix Metalloproteinases  
MRI  Magnetic Resonance Imaging  
MTP  Medial Tibial Plateau  
NGF  Nerve Growth Factor  
NSAID Non-Steroidal Anti-Inflammatory Drug  
OA  Osteoarthritis 
OCT   Optical Coherence Tomogrpahy  
PCL  Posterior Cruciate Ligament  
PTOA  Post-Traumatic Osteoarthritis  
RA  Rheumatoid Arthritis  
 xi 
ROM  Range of Motion 
SNP  Single Nucleotide Polymorphism  
STZ  Superficial/Tangential Zone  
TGF  Tumour Growth Factor 
TKR   Total Knee Replacement  
TLR  Toll-Like Receptor  
TNF  Tumor Necrosis Factor  
PRR  Pattern Recognizing Receptor  



















1   Introduction 
 
Musculoskeletal conditions are the leading cause of disability in Canada, with 
Osteoarthritis (OA) as the second most prevalent condition after lower back pain [1]. 
Arthritis is the leading chronic condition for Canadian adults and is expected to rise to 
almost 9 million cases by 2040 [2]. OA is a degenerative joint disease that leads to 
cartilage breakdown, boney deformation, and synovial inflammation [3]. Those impacted 
may have one or more synovial joints affected, with the hip, knee, hand, and spine most 
common, leading to limited mobility and pain [4]. OA pain results in people with arthritis 
being much more likely to report disability within all age groups and to drop out of the 
labour force [2]. The total direct cost of OA in Canada is expected to increase 2.6-fold 
by 2031, to $7.6 billion dollars, demonstrating its great economic burden [5]. Currently, 
there is no disease modifying agent for OA (DMOAD), so treatment focuses on pain 
management and total joint replacement in the end stage. In this chapter, I will examine 
the synovial knee joint, its response to OA, and the role of inflammatory mediators.  
 
1.1   The Synovial Joint 
 
Joints that have a synovial cavity between two articulating bones are classified as 
synovial joints. They have a range of motion depending on the shape of the articulating 
bones. Joints are complex organs, comprised of many different tissues that function to 
provide structural support, lubrication, and shock absorption. Synovial joints consist of a 
joint capsule (separated into a fibrous and synovial membrane), articular cartilage, 
subchondral bone, synovial fluid, and supporting structures (Fig 1.1) [6]. This section 






Figure 1.1 – The synovial joint in a healthy and osteoarthritic knee  
The synovial joint is a dynamic organ, comprised of a joint capsule, articulating 
cartilage, subchondral bone, synovial fluid, and supporting structures. These tissues all 
work together in order to provide structural support, lubrication, and shock absorption. 
Osteoarthritis affects each joint tissue in a unique way, resulting in articular cartilage 
breakdown, synovitis, and altered subchondral bone.  
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1.1.1   Articular Cartilage 
 
Cartilage is a prominent structural tissue within the body, distinguished into three 
categories: hyaline, elastic, and fibrous. Hyaline cartilage is the most abundant type in 
the body and plays an integral role within the joint. Articular cartilage is composed of 
hyaline cartilage, lining the ends of bones in diarthrodial joints. It functions to decrease 
friction and absorb/distribute forces during movement. The hyaline cartilage within the 
metaphysis has a specific role in long bone growth [7]. Cartilage is composed of one 
cell type, termed chondrocytes, that accounts for only 5% of the total tissue volume in 
humans. Chondrocytes are derived from mesenchymal progenitor cells but show little to 
no proliferation in adult tissue. The remaining 95% of cartilage is the extracellular matrix 
(ECM), with a vast majority (70-80%) of the ECM being water, with collagens and 
proteoglycans comprising the remainder. The tissue is avascular, depending on the 
surrounding synovial fluid for nutrient diffusion. The ECM collagen is overwhelmingly 
(90%) type II, with type I collagen only found in small amounts at the superficial zone 
[8]. The remaining 10% is believed to include type VI, IX, X, and XI collagens, although 
minor contributions of additional collagens have been described [8, 9]. The collagens 
provide structural support, as well as tensile and shear resistance. Additionally, the 
collagen helps restrain the proteoglycans in the ECM. Amongst the ECM proteoglycans, 
aggrecan is the most abundant, consisting of a core protein and glycosaminoglycan 
(GAG) side chains of chondroitin sulphate and keratin sulphate. The aggrecan is non-
covalently linked to a hyaluronic acid backbone through Link protein, creating a large 
polymer that is easier for the collagen to restrain. Most important is the negative charge 
of GAGs, as it is this feature that allows the proteoglycans to attract water during 
compression [8].  
 
Articular cartilage is classified into zones based on chondrocyte and collagen 
organization (Fig 1.2). The zones are as follows: (1) Superficial/Tangential Zone (STZ), 
(2) Middle/Transitional Zone, (3) Deep/Radial Zone, and (4) Calcified Zone [8]. The STZ 
comprises the upper 10-20% of tissue, with flat discoidal chondrocytes and densely 
packed collagen fibres oriented parallel to the surface. This zone is adapted to reduce 
 5 
friction through the secretion of specialized proteins, a high water content, and parallel 
collagen/chondrocyte arrangement. In fact, this zone demonstrates a 2 times greater 
Young’s modulus compared to the Middle and Deep Zones. The next 40-60% is the 
Middle Zone, with round chondrocytes in perpendicular columns and randomly oriented 
collagen fibres. This zone has the highest proteoglycan content. The Deep Zone 
comprises the last 30-40%, where the chondrocytes beginning to become more 
spherical and stack perpendicularly. The collagen fibres are thicker and serve to anchor 
the cartilage to the subchondral bone via perpendicular bundles [8]. Finally, the 
Tidemark is the distinguishing line between the calcified and non-calcified cartilage, 
establishing a transition between the cartilage and subchondral bone. The tidemark is 
part of the osteochondral junction, a functional unit consisting of the deep non-calcified 
cartilage, tidemark, calcified cartilage, cement line, and subchondral bone. This area 
has a strong biomechanical and biochemical connection, adapting to any changes 






Figure 1.2 – Articular cartilage is organized in distinct zones 
Articular cartilage is organized into four distinct zones based on the organization and 
characteristics of chondrocytes and collagen fibres. The Superficial Tangential Zone 
(STZ) has flattened chondrocytes with collagen fibres oriented parallel to the cartilage 
surface and is adapted to reduce friction. Next, the Middle Zone has round 
chondrocytes with collagen fibres in a random orientation, containing the highest 
proteoglycan content. In the Deep Zone, the chondrocytes and collagen fibres are 
perpendicularly stacked. Here, the collagen fibres are thicker and serve to anchor the 
non-calcified cartilage to the subchondral bone. Finally, the calcified cartilage is 
separated from the non-calcified cartilage by the tidemark. The tidemark, cement line, 





1.1.2   Bone & Subchondral Bone  
 
Bones are the structural framework of the body, accounting for 18% of body weight [11]. 
Additional functions include organ protection, load bearing, generating movement with 
coordinating muscles, blood cell production, endocrine functions, and mineral and 
triglyceride storage. Multiple tissue types make up bones, such as marrow, periosteum, 
endosteum, as well as a nerve and blood supply. Bone is majorly comprised of the 
mineral Calcium Phosphate (Ca3(PO4)2), as well as an organic component of type I 
collagen and non-collagenous proteins. The collagen fibres are layered at varying 
angles in order to provide greater structural integrity, guiding the direction of Ca3(PO4)2  
organization. Bone is subdivided into two categories: cortical/compact bone making up 
the majority of the diaphysis, and the trabecular/spongy bone at the core of the 
epiphysis. Three functional cell types contribute to bone tissue: osteoblasts, osteoclasts, 
and osteocytes. Osteogenic cells are derived from mesenchymal stem cells and 
differentiate into osteoblasts, which secrete collagen and other proteins in order to build 
bone ECM, eventually becoming trapped and maturing into osteocytes. Alternatively, 
osteoblasts may also become inactive bone lining cells or go through apoptosis. The 
osteocytes are found in lacunae, which are connected via small channels called 
canaliculi. Within these channels, neighboring osteocyte processes create gap junctions 
in order to communicate and maintain metabolism. Finally, osteoclasts, derived from 
myeloid lineage, are bone-resorbing cells, utilizing secretions of lysosomal enzymes 
and acid from its ruffled border to breakdown collagen and Ca3(PO4)2. The balance of 
osteoblast formation and osteoclast resorption defines the bone remodeling cycle, an 
asynchronous process integral to bone growth, maintenance, and repair [11].  
 
The definition of subchondral bone is not universal, varying from the tissue immediately 
below the articular cartilage tidemark, to being the trabecular bone adjacent to the 
cortical bone [12]. That being said, it is widely accepted that there are two distinct 
anatomical entities within the subchondral bone - the bone plate and the supporting 
trabeculae. The subchondral bone plate is the cortical endplate immediately under the 
calcified cartilage, or cement line. The subchondral trabecular bone, also referred to as 
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supporting trabeculae, is the area under the bone plate consisting of the trabecular 
bone and deeper bone structures [10, 12]. For the purpose of this thesis, “subchondral 
bone” refers to the subchondral bone plate and the supporting trabeculae. The 
subchondral bone plate is porous, with channels containing blood vessels and nerves 
from the marrow penetrating into the calcified cartilage. Interestingly, these dynamic 
channels vary with joint stress and cortical thickness. More channels will form in areas 
of high joint stress, such as the center of the tibial plateau, with a 15-25% increase in 
vessel density in these areas. As for cortical thickness, the channels are more narrow in 
thicker regions, leading to branch-like projections, compared to the wide, ampullae-like 
channels in the thinner areas [10, 12]. The bone plate varies in part due to the varying 
shape of the articulating surface, where the periphery is thinner. A regular and 
concentric thickness distribution is commonly found, for example the tibial plateau has a 
7- to 12-fold increase from the periphery to the center [12]. Underneath, the supporting 
trabeculae play an important role in shock absorption and metabolism. The tissue has 
an increased porosity compared to the cortical bone, containing blood vessels, nerves, 
and bone marrow, allowing for high metabolic activity. Additionally, its structure varies 
depending on articular cartilage distance [10].  
 
Subchondral bone plays a vital role in load bearing, working in complement with the 
articular cartilage. The bone absorbs the mechanical load from the articular cartilage, 
gradually transitioning the stress/strain [10]. The composition of bone is specialized to 
absorb this load from the overlying cartilage, as it is much stiffer and stronger. This is 
believed to aid in the bones ability to additionally dissipate juxta-articular loads [12]. 
Overall, the subchondral bone is a dynamic tissue, playing a major role in joint health 
and metabolism.  
 
1.1.3   Synovium 
 
The synovium is a vital joint structure, maintaining homeostasis, providing nutrients, and 
clearing waste. It is comprised of the synovial membrane, or intima, (mainly 
synoviocytes), and the sub-intimal space (fibrous connective tissue and blood vessels). 
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The synovium’s secretion of synovial fluid is one of its most important functions. This 
viscous fluid functions to reduce friction, aid in shock absorption, supply 
oxygen/nutrients, and remove waste. Without it, the avascular cartilage would not be 
able to maintain homeostasis [6]. Synovial fluid is derived from interstitial fluid as a 
blood ultra-filtrate, containing hyaluronic acid and lubricating molecules, which provide 
non-Newtonian properties to the fluid. Additionally, there are inorganic salts such as 
sodium, potassium, calcium, and chloride within the fluid. When shear force is applied, 
the fluid viscosity increases in order to absorb the force, and then immediately 
decreases viscosity with either the removal of force or prolonged stress [8]. 
There are two types of synoviocytes within the synovial membrane: the fibrous-like 
synoviocytes (FLS) are specialized secretory cells, and the macrophage-like 
synoviocytes (MLS) clear joint debris [13]. The FLS (type B synoviocytes) are the 
predominant cell type, accounting for 75% of all cells in the intima. Collagen, fibronectin, 
hyaluronic acid, lubricin, and other GAGs are all secreted by the FLS into the synovial 
fluid, under the influence of signals from the neighboring fenestrated capillaries [13, 14]. 
Hyaluronic acid plays an important aspect in joint health, maintaining synovial fluid 
viscosity and assisting in joint cushioning, while lubricin is the most prominent 
lubricating protein [13, 15]. Finally, in vitro and ex vivo studies have found the potential 
for FLS to differentiate into chondrocytes, providing a cell source for cartilage 
regeneration [13].  
 
The MLS (type A synoviocytes) play a key role in joint health as they are specialized to 
phagocytose ECM constituents, cell debris, microorganisms, and antigens in the 
synovial fluid [14]. They also regulate the levels of pro- and anti-inflammatory cytokines 
through their phenotypical variants. M1, or classically activated macrophages, are  
pro-inflammatory, while the M2, or alternatively activated macrophages, are  
anti-inflammatory mediators. Following joint trauma, bone marrow derived macrophages 
(non-tissue resident) are quickly recruited due to their proximity to blood vessels, 




The sub-intima is categorized as fibrous, areolar, or adipose tissue, containing type I 
collagen and a healthy supply of blood, nerve, and lymphatic vessels. This layer is up to 
5 mm thick, although there may be no discrete membrane in some areas due to 
surrounding tissue. The areolar type is the most specialized type of sub-intima, with 
viscoelastic properties to cope with stretching and rolling during dynamic movement 
[17].  
 
1.1.4   Supporting Structures 
 
Supporting structures play an additional role in joint stability and mobility, varying across 
joints based on their required function. These include, but are not limited to, ligaments, 
tendons, menisci, bursa, and labrum [6]. Ligaments may be categorized as extra- or 
intra-capsular, an important distinction both anatomically and in terms of swelling. In the 
knee, the collateral ligaments are extra-capsular and the cruciate ligaments are intra-
capsular, the latter of which has significantly increased swelling following injury. 
Regardless, both types play an important role in joint stability during dynamic movement 
[18, 19]. The knee also contains two menisci, a fibrocartilage structure resembling a 
disc that assists in shock absorption [6]. The menisci are stabilized within the joint via 
the transverse ligament, as well as attachments to the femur and tibia to prevent 
dislodging during compression. Blood supply is limited to the outer portion of the tissue, 
leaving the remaining 65-75% depending on the synovial fluid for nutrients. The 
meniscus has functions in addition to shock absorption, such as secondary joint 
stabilization, stress distribution, joint protection, and cartilage nutrition and lubrication. 
Meniscus loading across the tissue varies from 45-70% of the weight-bearing load, 
demonstrating a significant role in attenuating forces to the cartilage and bone. Similar 
to the articular cartilage, the collagen fibres (type II here) demonstrate zonal 
organization in order to best distribute load [20]. Finally, the muscles and tendons work 





1.2   OA Pathophysiology  
 
OA is a disorder of the entire joint, initially categorized by abnormal joint tissue 
metabolism and later by physiological changes, including cartilage degeneration, bone 
remodeling, osteophyte formation, inflammation, and loss of joint function (Fig 1) [3]. It 
is more than just a disorder of the articular cartilage, with varying effects on each tissue 
in the joint. Each tissue reacts in its own way to the disease, as well as to the actions of 
the other joint tissues. OA is a heterogenous, multifactorial disorder, leading to varying 
presentations of the disease. This section serves as an overview of the effects of OA on 
each joint tissue, with a closer analysis of variation in Section 1.6. 
 
1.2.1   Articular Cartilage Effects  
 
OA can be initiated through a number of mechanisms, including injury. The articular 
cartilage is generally the first tissue thought of when discussing the effects of OA. Early 
in the disease, chondrocytes will attempt to proliferate to repair damage, which results 
in chondrocyte clusters as well as an increase in ECM secretion. Subsequently, 
catabolic activity increases in the joint, leading to the degradation of type II collagen and 
the proteoglycans within the ECM. Additionally, changes to regulatory proteins, matrix 
proteins, stress markers, apoptotic markers, and transcription factors are found [21].  
Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that play a major role in 
ECM degradation through the cleaving of type II collagen. Additionally, they may cleave 
cell surface receptors and other ECM components (e.g., aggrecan, fibronectin, laminin). 
MMPs are synthesized and secreted by fibroblasts and chondrocytes in the joint, 
influenced by the activity of cytokines. Many MMPs have been studied within OA 
pathophysiology, with MMP-1, -8, and -13 as the major collagenases. Increased  
MMP-13 expression is one hallmark of OA and has a preference for destruction of type 
II collagen [22]. Interestingly, MMP-13 is secreted by chondrocytes in healthy adults, but 
is quickly endocytosed and destroyed [23]. Animal studies have been instrumental in 
the understanding of the role of MMP-13 and OA. Neuhold et al. (2001), found that mice 
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with a cartilage-specific increase in MMP-13 activity had increased articular cartilage 
destruction, similar to what is seen in OA pathology [24]. Further work by Little et al. 
(2009) used an MMP-13-/- mouse model with surgically induced OA and found that the 
MMP-13-/- mice had less cartilage damage, compared to wild-type mice [25]. This was 
confirmed by Wang et al. (2013), who used a mouse model with cartilage-specific  
MMP-13 deletion, finding a decrease in cartilage damage at 8, 12, and 16 weeks post 
OA-inducing surgery [26]. Overall, the MMPs, and specifically MMP-13, work to 
decrease the structural integrity of cartilage through cleavage of type II collagen and 
other substrates [22 – 26].  
 
Cartilage integrity is diminished further by ADAMTS aggrecanases (a disintegrin and 
metalloproteinase with thrombospondin-like motifs), which breakdown the ECM. In fact, 
aggrecan loss is the first measurable difference in the ECM during OA pathogenesis 
[27]. The loss of aggrecan is primarily due to ADAMTS aggrecanases, with ADAMTS-4 
and -5 studied the most with respect to OA. Both work to cleave aggrecan at the 
aggrecanase-specific Glu373-Ala374 site and are the most efficient aggrecanases [27]. 
A 2002 study by Malfait et al. determined that inhibition of ADAMTS-4 and -5 (via BB-
16) successfully blocked aggrecan destruction in OA cartilage in vitro [28]. Majamdar et 
al. (2007) later generated ADAMTS-4/5 double knockout mice and surgically induced 
OA to further study their role. They found that the double knockout mice were protected 
against OA-related proteoglycan loss, which was comparable to the ADAMTS-5 single 
knockout mice, but not the ADAMTS-4 single knockout mice [29]. That being said, 
ADAMTS-5 has not been widely accepted as the main aggrecanase in humans as the 
relationship is more complex [27]. The loss of aggrecans in the ECM results in cartilage 
that is not able to hold in water, thus losing its viscoelastic properties.   
 
Damage to the articular cartilage can be tracked histologically in animal models, where 
surface fibrillations, ECM loss as seen by the lack of GAG staining, and chondrocyte 
hypertrophy are seen in the earliest stages. As the disease progresses, articular 
cartilage loss expands from the surface to the tidemark [30]. 
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1.2.2   Subchondral Bone Effects  
 
Alterations to the bone are a direct consequence of the changes in the joint environment 
during disease progression. In general, these changes include subchondral plate 
thickening, trabecular bone changes, osteophyte formation, and subchondral bone 
cysts. According to Wolff’s law, bone adaptation is based on the magnitude and 
direction of applied force, suggesting that OA changes in the bone are a result of load 
pattern changes [31]. Early-stage OA is defined in the bone by structural deterioration 
and increased bone turnover, with several factors implicated. These include 
microdamage repair, angiogenesis, and increased subchondral plate porosity [32 – 34]. 
Microdamage may be linear (up to a few hundred microns long) or diffuse (patches of 
damage), although osteocytes activate resorption in response to linear microcracks only 
[32]. These microcracks occur in both the bone plate and supporting trabeculae, serving 
two functions: (1) act as the site of bone remodeling and (2) act as a communication 
conduit between cartilage and bone. Linear microcracks initiate bone remodeling via 
osteocyte apoptosis, leading to a high bone turnover. This subsequently leads to a 
thickened subchondral plate and an advancement of the tidemark due to thickened 
calcified cartilage, ultimately leading to cartilage thinning [32]. As for angiogenesis, this 
process occurs as blood vessels from the subchondral bone invade the tidemark in 
regions of proteoglycan loss, with vascular density increasing as OA progresses. Like 
the microcracks, this ultimately leads to cartilage thinning as the calcified cartilage 
advances upwards [33]. Finally, an increase in subchondral plate porosity was 
demonstrated by Iijima et al. (2016), where rats with surgically induced OA showed an 
increase in porosity within 2 weeks post-operation. The increase in porosity coincided 
with adjacent subchondral bone damage and cartilage loss, and was localized to the 
area of greatest joint loading [34]. 
 
Osteophytes are fibrocartilaginous/boney growths localized to joint margins, and are a 
hallmark of radiographic OA. Animal studies have shown that osteophytes form as a 
result of periosteal cell proliferation and subsequently differentiation into chondrocytes, 
which undergo endochondral ossification [21]. Growth factors such as Tumor Growth 
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Factor 𝛽 (TGF𝛽)	and Bone Morphogenic Protein-2 (BMP2) are implicated in osteophyte 
formation, offering a potential therapeutic target [35]. As previously described, Wolff’s 
law may explain osteophyte growth, as the changing pattern of joint loading may lead to 
these boney growths in an attempt to maintain joint stability [21].  
 
Further, bone cysts and bone marrow lesions are another commonly seen sign of 
progressive OA, with bone cysts leading to an increased risk of total knee replacement 
(TKR) [36]. Bone cysts are composed of fibroconnective tissue filled with fluid, easily 
seen on MRI, although they may ossify as the disease progresses. Bone cysts have two 
potential origins: synovial fluid intrusion or bone contusion. The first theory assumes 
that the breach of the osteochondral junction allows for synovial fluid infiltration, thus 
leading to bone cysts. In the bone contusion theory, the cysts are due to microcracks 
and focal bone resorption leading to necrotic lesions [10]. As for bone marrow lesions, 
they have been observed in healthy patients, although large lesions are associated in 
knee OA with an increased rate of cartilage loss [37]. This relationship is strengthened 
by work from Zhao et al. (2010), who utilized MRI technology to demonstrate that bone 
marrow lesions are preferentially located in areas of cartilage lesions, and the levels of 
cartilage loss is proportional to bone marrow lesion signal intensity [38]. Overall, the 
bone is widely affected by OA pathophysiology.  
 
1.2.3   Synovitis  
 
The inflammation of the synovium, termed synovitis, may be caused by joint trauma, 
infection, and/or joint damage. A failure to resolve this inflammation results in drastic 
changes to the resident cells, with hyperplasia, angiogenesis, and infiltrates within the 
synovial membrane. Infiltrating cells, such as T-cells, B-cells, plasma cells, and 
macrophages, result in destruction of the cartilage matrix and subchondral bone 
[13]. Synovitis is common in knee OA and its presence is clearly correlated to OA 
progression. Felson and colleagues (2015) determined that synovitis is an independent 
risk factor for knee OA development, and Roemer and colleagues (2011) found that 
effusion synovitis was predictive of cartilage loss [39, 40]. The mechanism of this 
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increased damage is via synoviocytes and macrophages, which increase the production 
of pro-inflammatory cytokines and thus catabolic factors in the joint [41]. This has a 
distinct importance for patients, as knee synovitis carries a 9.2-fold increase in pain 
severity and is more likely to lead to TKR [42, 43]. The increase in pain could be due to 
a heightened pain sensitization from increased peripheral nociceptor activity [44]. The 
synovium is a dynamic structure that requires further focus in OA research.  
 
1.2.4   Supporting Structures Effects  
 
While damage to supporting structures, such as ligaments and meniscus, may cause 
traumatic knee OA, these structures are also vulnerable to OA damage without trauma. 
Muscle atrophy is positively correlated with OA disease progression and affects type I 
and type II muscle fibres [45]. Analysis of the lateral and medial meniscus in OA 
patients demonstrates fibrocartilage calcification and fraying, cell clustering, and cell 
hypertrophy [46]. Further, there is an increase in blood vessel density and sensory 
nerves in the meniscus during OA, serving as a potential source of knee OA pain [47]. 
As for ligaments, the cruciate ligaments may be affected, with the Anterior Cruciate 
Ligament (ACL) more so than the Posterior Cruciate Ligament (PCL). Mullaji et al. 
(2008) compared the ACL and PCL of end-stage knee OA patients, finding that the ACL 
was most severely affected in patients who had a radiographic OA score of 3 and varus 
deformity > 15 degrees. These changes are believed to be due to the changes in the 
force placed on the ACL during flexion/extension, due to altered load mechanics [48]. A 
later study by Hasegawa et al. (2012) found that changes to the ACL (collagen 
disorganization, mucoid degeneration, and chondroid metaplasia) was correlated to the 
presence of OA pathology [49]. The effects of OA on the supporting structures requires 
further research in order to understand the full spectrum of the disease and how to best 
therapeutically intervene. Future studies should also look to more rigorously control for 




1.3   Risk Factors and Diagnosis  
 
OA diagnosis is based on risk factors, clinical manifestations, and imagining modalities. 
Risk factors should first be considered, which include age, sex, obesity, occupation, and 
joint injury. Age is the greatest risk factor for OA, although this could be due to its close 
relation to the other risk factors, as well as cell senescence [50, 51]. Females are at a 
higher risk than males to develop knee, hip, and hand OA, with risk increasing at the 
age of menopause [51]. Obesity is a risk factor for both weight bearing (ex. knee) and 
non-weight bearing (ex. hand) joints, demonstrating that it plays a more complex role 
than simply increased joint loading. The adipose tissue most likely increases the 
secretions of pro-inflammatory factors, leading to a chronic low-grade inflammation [52]. 
Physically demanding jobs, such as farming or carpentry, increase the risk of lower limb 
OA due to the associated tasks of squatting, lifting, and prolonged standing [53]. 
Previous joint injury, such as ligament/meniscal tears, can lead to OA due to an 
abnormal inflammatory response, discussed more in Section 1.7 [54]. Collecting a 
comprehensive medical history is an important step in the process of OA diagnosis, but 
it cannot serve as the sole indicator of the disease.  
 
Clinical manifestations of OA include joint pain that improves with rest, morning stiffness 
(less than 30 minutes), functional limitations, crepitus, and boney deformity. Joints are 
typically asymmetrically affected, with the hands, knees, hips, and spine most 
commonly involved. Physical examinations are used to test the painful range of motion 
(ROM), ROM limitations, crepitus, and joint instability. There is no specific and sensitive 
laboratory test for OA, and so an assessment of risk factors and physical examination 
provide enough information to confidently diagnose OA [55]. 
 
Imaging provides an opportunity to visualize any abnormalities within the joint and 
allows for disease staging. Radiography is the most accessible and thus most 
commonly used imaging modality for diagnosis [56]. The Kellgren-Lawrence (KL) score 
is a widely used radiographic classification system ranging from 0 to 4, where 0 
represents no OA and 4 is severe OA. The system is based on the presence and 
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severity of osteophytes, joint space narrowing, sclerosis, and altered bone shape [57]. 
New methodologies have been used to increase visualization in the knee, where 
instead of the traditional extended position, a flexed knee with various x-ray beam 
angles are used [56]. Other, less commonly used forms of imaging include MRI, OCT, 
and ultrasound. Magnetic Resonance Imaging (MRI) is a useful tool for examining entire 
joint pathology, as it is accurately able to discriminate articular cartilage, meniscus, and 
ligaments. Optical Coherence Tomography (OCT) is a real-time analysis of joint tissue, 
as it is done during arthroscopy and provides cross-sectional images of the cartilage. 
Finally, ultrasound technology is a cost-effective method of multiplanar imaging that is 
able to assess dynamic structures in real time [56]. Overall, these imaging modalities 
are only recommended for clinical use when the OA diagnosis is in doubt due to their 
high cost, but are an excellent tool for research use [55].   
 
1.4   Pain 
 
Pain is the predominant reason for OA patients to seek medical care, with 
approximately 39% of OA patients reporting moderate to severe pain, and a 4 times 
higher rate of avoiding daily actives due to this pain [2]. The early stages of disease are 
marked by joint pain that improves with rest, but gradually increases over time and may 
become a constant nocturnal pain. During this time, sleep disruption is often met with 
mood disorders and fatigue [58]. In fact, it is reported that 60% of OA patients 
experience trouble sleeping, leading to a generalized fatigue that is strongly associated 
with worsening mental and physical health [2, 59]. Patients also have an increased risk 
of developing mood disorders and anxiety, especially within the 35-44 year-old age 
group, who are 3 times more at risk than those without arthritis [2]. In addition to 
localized pain, patients report an increase in pain sensitization, which is believed to be 
due to alterations in nociceptive processing in the peripheral and/or central nervous 
system. Peripheral sensitization may be due to inflammation affecting local deep 
somatic nociceptors, while central sensitization is thought to be due to pathological 
neural signals from the affected joint changing the CNS [58, 60]. Pain sensitization, 
measured through temporal summation, is significantly associated with symptom 
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severity but not radiographic severity. Additionally, reversibility of sensitization has been 
seen following TKR at all sites, and pre-surgical pain sensitivity predicts worse pain 
outcomes following TKR [60]. Pain sensitization is a complex process that requires 
further research to establish a definitive pathway and treatment.  
 
Interestingly, radiographic severity and pain severity do not consistently correlate. As 
seen by Creamer et al. (1999), KL grades demonstrate a poor correlation across three 
different, validated self-reported measures of pain [61]. A high pain severity with low 
radiographic severity may be explained by an increase in disease activity, as OA 
patients with frequent pain have a greater rate of change than pain-free OA patients 
[62]. So, while pain may not accurately predict radiographic severity, it is more 
accurately an indicator of disease activity [58, 62]. The exact cause of pain within the 
joint is most likely not from the cartilage, as it is aneural, leading to the synovium and 
bone as the tissues of interest. Large bone marrow lesions are associated with greater 
self-reported pain, with decreased pain as the lesion size decreases [63]. As for 
synovial inflammation, Baker et al. (2010) reports a 9.2-fold odds increase in knee pain 
in the presence of synovitis [42].  
 
Molecular and cellular mechanisms of OA pain include signaling through nerve growth 
factor and cytokines, as well as angiogenesis. Nerve growth factor (NGF) is crucial for 
nociceptor development and its blockade shows promising results in animal work [64]. A 
monoclonal NGF antibody, termed tenazumab, successfully decreases pain, stiffness, 
and limitations in physical functions in human OA trials, lasting up to 56 weeks [65, 66]. 
Unfortunately, bone necrosis is found in some patients, leading to a pause in the clinical 
trials [65, 67]. As for cytokines, some act as pro-nociceptive mediators and may 
sensitize Ad- and C-fibres, although human clinical trials targeting some of these have 
not been successful [56]. Finally, angiogenesis may be targeted through 
dexamethasone (a corticosteroid), indomethacin (a non-steroidal anti-inflammatory 
medication), and PPI-2458 (an antiangiogenic fumagillin analog). These compounds 
successfully reduce pain, synovial inflammation, and synovial angiogenesis in rat 
models, to varying degrees [47]. Reducing angiogenesis could also play a role in the 
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subchondral bone, as the increase in subchondral channels containing blood vessels 
and nerves during OA could be a source of pain and inflammation [58].   
 
1.5   Treatment 
 
There is currently no disease modifying OA drug (DMOAD), so treatment is focused on 
pain management, with total joint replacement at the end stages. Non-surgical 
treatment is recommended based on comorbidities, as outlined by OARSI guidelines 
[68]. Treatment for knee OA specifically is outlined here, as there are some variations 
depending on disease location. Land based exercise (e.g., yoga, Tai-Chi), weight 
management, and arthritis education are recommended for all knee OA patients, 
regardless of comorbidity. Exercise helps relieve pain, and in the case of Tai-Chi is an 
effective method of increasing neuromuscular communication. Weight management 
prevents newer or worsening metabolic-OA, and arthritis education assists in patient 
expectation and disease perception. Other non-pharmacological treatments include 
aquatic exercise and gait aids (e.g., cane, walking aid), although these are conditional. 
For example, aquatic exercise specifically has many potential accessibility issues with 
regards to cost and is not recommended for those with frailty [68].  
 
Pharmacological interventions target pain but not the underlying cause and may include 
side effects. Paracetamol, although commonly used, does not have a significant efficacy 
and may lead to liver toxicity, and is therefore not recommended by OARSI [68, 69]. 
Topical non-steroidal anti-inflammatory drugs (NSAIDs) are strongly recommended if 
there is no comorbidity, and provide modest benefits with minimal adverse events. Oral 
NSAIDs are conditionally recommended, with a preference for non-selective NSAIDs 
with a proton pump inhibitor or selective COX-2 inhibitor. For patients with depression, 
duloxetine and cognitive behavioural therapy is recommended [68].  
 
Novel treatments for pain management in OA are being examined. Topical capsaicin 
treatment has been used as an analgesic, so a highly purified and injectable form 
(CNTX-4975) was established for studies. A multi-centre randomized, double-blind, 
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placebo-control phase 2 study found that intra-articular injection with CNTX-4975 had 
clinically relevant pain relief for a prolonged period of time, establishing a rationale for 
further studies [70]. Studies using biologics have also gained interest in OA treatment, 
such as those targeting interleukin-1 (IL-1) and tumour necrosis factor (TNF). IL-1 is 
successfully blocked by lutikizumab, but this compound did not consistently provide pain 
relief and did not have an effect on synovitis in OA [71, 72]. As for TNF blockage with 
etanercept, pain relief was observed in an inflammation subgroup after 1 year, but there 
was no significant relief for the primary group after 2 years. There was no evidence of 
improved synovitis, but some improvement in bone marrow lesion score. Therefore, it 
seems that anti-TNF treatments warrant further research, specifically for patients with 
active inflammation [73]. 
 
Intra-articular injections are conditionally recommended for both intra-articular 
corticosteroids (IACS) and intra-articular hyaluronan (IAHA). IACS potentially provide a 
shorter term pain relief compared to IAHA, which might provide longer relief and less 
adverse events, although this is controversial [68]. While commonly used, there is rising 
evidence that IACS lead to increased radiographic severity, with cartilage loss and joint 
space narrowing observed [69]. IAHAs, although controversial, are available in multiple 
forms, varying in production and concentration, and may provide significant pain relief. 
Overall, IAHAs are well tolerated and adverse events tend to be minimal and mild, with 
the exception of Synvisc. This version of IAHA therapy has been reported to lead to 
severe acute inflammatory reactions or pseudo-septic reactions, demonstrating a need 
to examine each form of IAHA separately [15]. 
 
Finally, the most common treatment for end stage OA in the hips and knees is a total 
joint replacement [74]. Surgery is considered at the end stage when there is a 
considerable decrease in joint function and increasing pain. In general, current joint 
prostheses should function for 15 to 20 years, although revision surgery due to 
instability is possible [55]. Total knee replacement is generally believed to have good 
rates of patient satisfaction, although there is quite a variance, most likely due to issues 
in methodology. For instance, only 13% of studies in a systematic review used validated 
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satisfaction surveys, and 21.2% failed to define a system for satisfaction measurement, 
making it hard to accurately extrapolate data [75]. 
 
1.6   Stratification of OA 
 
OA is a heterogeneous, multifactorial disorder that is generally classified as primary 
(idiopathic) or secondary (e.g., joint injury), an important distinction for treatment 
guidelines [76]. Creating distinct phenotypes is difficult as one patient may have multiple 
risk factors or develop them as the disease progresses. Attempts to define subgroups 
has varied from etiology, genetics, anatomy, and radiographic phenotypes [77]. A recent 
systematic review found that studies on knee OA phenotypes focused on a single 
domain, such as clinical, imaging, or laboratory phenotypes, and are limited as they 
rarely combined the data. The review did not create distinct subpopulations, but did 
conclude that pain sensitization, psychological distress, radiographic severity, body 
mass index, muscle strength, inflammation, and comorbidities are all clinically distinct 
[78]. Another systematic review of knee OA concludes 6 phenotypes: (1) chronic pain, 
(2) inflammatory, (3) metabolic syndrome, (4) bone and cartilage metabolism,  
(5) mechanical overload, and (6) minimal joint disease, but cautioned that it is not clear 
if these are discrete [79]. The need to stratify in OA research, even with animal models, 
is stressed by recent work by Maumus et al., (2020), who compared 6 OA models in 
mice (surgical, aging, inflammatory, obesity, overweight, and metabolic syndrome) on 
their effect on the TGF𝛽 signaling pathway. The models were lacking a single common 
gene signature even though the OA scores were similar, demonstrating the importance 
of clear stratification and avoiding extrapolating information across models [80].  
 
1.7   PTOA 
 
Post-traumatic osteoarthritis (PTOA) is a subtype of OA that develops after joint injury, 
such as meniscal or ligament injury, typically in the lower extremities [81]. PTOA is 
estimated to account for 12% of all lower extremity OA cases with costs of about $3 
 22 
billion USD annually [82]. It may affect any joint, but has the highest incidence in the 
knee and ankle [81]. This is especially a concern for young athletes, who often sustain a 
knee injury during high school or college sports. In fact, knee injuries account for 15% of 
all high school sports-related injuries and 44.6% of surgeries, most commonly due to 
complete ligament tears [83]. Knee injury increases the risk of OA 4-fold across all ages 
[84]. Of those, ACL and meniscal injuries carry a high risk of PTOA development, with 
up to 13% of ACL injuries leading to PTOA, increasing to 21% - 48% for combined ACL 
and meniscal injuries [85]. Following ACL injury, there is a 1% increase in cartilage 
lesion risk for each month without surgery [86]. However, another study found that the 
re-stabilization surgery does not reduce the risk for PTOA, demonstrating that there is 
more than just biomechanics at play [87].  
 
A proposed mechanism of PTOA is the perpetuation of inflammation, in which some 
patients are unable to resolve the acute inflammation following joint injury and thus 
develop chronic inflammation that leads to PTOA [54]. This is supported by research by 
Sward and colleagues (2012), who collected synovial fluid at various timepoints (up to 
23 days) for patients with acute knee injury and assessed the levels of pro-inflammatory 
cytokines. Levels of IL-1𝛽, IL-6, and TNF𝛼 were highest 1 day after injury, then dropping 
while remaining statistically higher than in healthy knees [88]. The levels of pro-
inflammatory cytokines in the synovial fluid may remain elevated up to 6 months post 
injury, with distinct patterns depending on the stage of inflammation [54, 89]. Certain 
factors may increase the risk of this chronic inflammation, such as injury severity, 
repetitive injuries, and an imbalance of pro- and anti-inflammatory factors during the 
acute and sub-acute period [54]. Work by Heard and colleagues (2013) demonstrates 
how sustained inflammation increases PTOA using an ovine model that had an ACL 
transection with immediate reconstructive surgery. They found that cartilage damage 
and osteophytes occurred 2 weeks post-operatively, but did not progress by 20 weeks 
post-op. Similarly, pro-inflammatory cytokine levels were initially increased, but 
normalized by 20 weeks, suggesting the acute inflammatory phase successfully 
resolved [90]. Exploring both pharmacological (anti-cytokine therapy) and non-
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pharmaceutical (exercise) methods to ensure the resolution of inflammation is a 
worthwhile endeavor in order to reduce PTOA risk [54]. 
 
1.8   Inflammation in OA 
 
Inflammation is a physiological response to irritants (e.g., pathogens, physical injury) in 
the body that leads to swelling, pain, and redness [91]. Inflammation in arthritis is 
typically associated with rheumatoid arthritis (RA), a systemic disease with joint swelling 
and damage, although it plays a role in OA as well [92, 93]. OA inflammation is distinctly 
different from RA in many ways, with OA having lower levels of inflammatory proteins, 
less pronounced synovitis, and no response to conventional biologics used in RA, to 
name a few [93]. OA is characterized by a chronic, low grade form of inflammation that 
involves the innate immune system. Joint trauma, chronic injury, or overuse have the 
potential to trigger this response through a number of mechanisms, including the pattern 
recognizing receptor - damage associate molecular pattern (PRR-DAMP) system, the 
complement system, macrophage response, and cytokines [93]. 
 
PRR-DAMPs, the complement system, and macrophages are all part of the innate 
immune system. PRRs are the first line immune response, recognizing pathogen-
associated molecules through cell surface, endosomal, and cytosolic receptors. PRRs 
are also able to recognize damage-associated molecular patterns (DAMPs), which are 
endogenous molecules created during tissue damage that signal the immune system 
the need for repair. PPRs are classified based on location, with the membrane bound 
toll-like receptors (TLR) the most commonly associated with OA. As for OA-associated 
DAMPs, there are 4 subgroups; (1) ECM breakdown by-products, (2) plasma proteins, 
(3) intracellular alarmins, and (4) microscopic crystals [94]. PRR-DAMP activation of 
TLRs may lead to synovitis and cartilage degeneration, although in vivo testing with 
agonists yielded mixed results [93].  
 
Similarly, the complement system is the immune system mechanism to recognize 
pathogens, leading to increased phagocytosis. Activation of the complement system 
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forms C3 and C5 convertases, which activate the membrane attack complex (MAC) to 
form transmembrane pores on cells to cause lysis. If levels are sublytic,  
pro-inflammatory signaling is activated through the mitogen-activated protein kinase, the 
Janus kinase-signaling transducer and activator of transcription (JAK-STAT) pathway, 
and the nuclear factor kappa B (NF-𝜅B) pathway [93]. Mouse studies show that a C5 or 
C6 deficiency attenuates OA and hyper-activation of MAC formation increased OA 
pathology [95]. 
 
Finally, macrophages are implicated as they may be activated by DAMPs and 
complement, leading to increased cartilage breakdown and subchondral bone changes 
[93]. The presence of macrophages in the synovium is positively correlated to increased 
joint pain and stiffness, and a reduced quality of life [16]. This is due to their secretion of 
pro-inflammatory cytokines and MMPs, which is not balanced by the secretion of anti-
inflammatory factors and thus leads to increased cartilage breakdown. Therefore, 
macrophage ablation has been explored as a therapeutic treatment, with varying 
success [16]. For example, a mouse model using conditional macrophage depletion, 
with a high fat diet and surgically-induced OA found a massive infiltration of immune 
cells into the injured joint and increased concentrations of pro-inflammatory cytokines in 
the macrophage-depleted mice [96]. 
 
1.9   Cytokines  
 
Cytokines are secreted proteins that have a specific effect on the communication 
between cells that are often redundant, with multiples cytokines having similar functions.  
They are classically categorized as pro- or anti-inflammatory and are secreted by many 
cell types, such as synoviocytes, chondrocytes, and macrophages [97]. Pro-
inflammatory cytokines are a focus of OA pathophysiology as they increase catabolic 
factors in the joint, with IL-1 and TNF receiving particular attention [98]. Healthy 
synovium does have pro-inflammatory cytokines present, although there seems to be a 
higher presence of anti-inflammatory cytokines that successfully suppress inflammation 
[17]. An imbalance in this relationship leads to the inflammatory response seen in OA. 
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In fact, levels of IL-1𝛽 and TNF are increased in the synovial fluid, synovium, 
subchondral bone, and cartilage of the OA joint [99]. IL-1𝛽 and TNF will stimulate 
increased MMP release from chondrocytes and up-regulate ADAMTS-4, leading to 
collagen breakdown and proteoglycan loss. Additionally, both will cause an increase in 
other pro-inflammatory cytokines that will further increase MMP and ADAMTS activity, 
as well as cause the release of nitric oxide (NO) and prostaglandin E2 (PGE2) to 
enhance MMP activity [98].  
 
In contrast, anti-inflammatory cytokines work to suppress the actions of pro-
inflammatory cytokines, like IL-1𝛽 and TNF [100]. For example, IL-4 and IL-10 inhibit 
MMP activity and chondrocyte apoptosis, thus exhibiting a chondroprotective ability.  
IL-4 specifically is able to decrease the effect of IL-1 and TNF on NO production in vitro, 
whereas IL-10 stimulates the synthesis of type II collagen and aggrecan [100, 101]. 
That being said, anti-inflammatory cytokines do not have a primary prophylactic 
capability but instead are the response to the inflammatory response in OA. 
Unfortunately, there has not been success in anti-inflammatory based OA treatment 
[100]. For example, human clinical trials targeting IL-1𝛽 and TNF have not been 
successful even although animal trials have been encouraging. This may be due to the 
redundant manner of cytokines, an inability of these drugs to penetrate the joint, or 
testing at the end stage of disease when there may not be a profound effect [98].  
 
1.9.1   IL-15  
 
Interluekin-15 (IL-15) is a pro-inflammatory cytokine that is crucial for natural killer cell 
(NK) ontogeny and CD8 T cell memory. It is believed that IL-15 is mainly regulated at 
the post-transcriptional level [102]. There are 3 receptors for IL-15: (1) the specific  
IL-15R𝛼, (2) the shared IL-2/IL-15R𝛽, and (3) the common IL-15R𝛾, binding IL-15, -2,    
-4, -7, and -19. IL-15 has a high affinity (Ka ≥ 1011 M-1) for the IL-15R𝛼 chain, but can 
only transduce signals in the presence of the IL-15𝛽 and 𝛾 receptors, for which there is 
intermediate affinity (Ka = 109 M-1). The IL-15R𝛽 and 𝛾 chains signal via the Janus 
kinase-1 (Jak1) and Jak3 to activate Signal Transducer and Activator of Transcript 3 
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(STAT3) and STAT5, respectively. IL-15 has also been shown to activate the NF-𝜅B 
pathway [100]. IL-15 is widely expressed by monocytes, macrophages, dendritic cells, 
fibroblasts, epithelial cells, and skeletal muscle [103]. Additionally, IL-15 signaling plays 
a vital role in the bone turnover process. IL-15R𝛼 ensures efficient osteoblast/osteoclast 
coupling, as well as determining osteoblast phosphate homeostasis and mineralization 
capacity [104]. Il15R𝛼-/- female mice have impaired osteoclast activity and are protected 
from age related trabecular bone loss when ovariectomized [105]. Indeed, single 
nucleotide polymorphisms (SNP) of IL-15R𝛼 correlates to total bone volume, as well as 
cortical bone volume [106]. Overall, IL-15 plays an important role in many body tissues 
and processes.  
 
The relationship between IL-15 and RA has been more thoroughly investigated, as  
anti-IL-15 treatment has a potential therapeutic effect, although it may play a role in the 
chronic, low grade inflammation of OA [107]. IL-15 protein and mRNA levels are 
reported to be significantly increased in patients with OA compared to the control group 
[108]. Further, Scanzello et al. (2009) establish that IL-15 protein levels are higher in the 
synovial fluid during early OA compared to late stage, perhaps demonstrating activation 
in the early stages of the disease [109]. Interestingly, another study examining the 
correlation between SNPs in human IL-15R𝛼 and OA found an increased symptom risk 
by 1.5-fold [110]. Additionally, serum IL-15 levels independently correlate to pain 
intensity as measured by the Western Ontario McMaster University Osteoarthritis Index 
(WOMAC), although they do not correlate with KL radiographic severity [111]. The 
increase of IL-15 in the synovial fluid of OA patients is additionally positively correlated 
to other pro-inflammatory cytokines, as well as MMP activity [107, 112]. Specifically, 
Tao and colleagues (2015) demonstrate a strong correlation between MMP-7 serum 
levels and IL-15 [108]. A recent study determines that the IL-15R𝛼 is present on 
chondrocytes, and when treated with IL-15 in vitro there is an increase in MMP1 and -3 
release, but not in sGAG fragments [110]. Therefore, IL-15 may play a role in OA 
pathogenesis through an increase in pro-inflammatory activity that additionally creates 
more MMP activity. This MMP activity may then lead to increased tissue breakdown, 
and thus more pain and other symptoms.   
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Successful deletion of the Il15 gene in Holtzman Sprague-Dawley rats is demonstrated 
by Renaud and colleagues (2017). Utilizing zinc finger nuclease-mediated genome 
editing, the second coding exon of Il15 was targeted with the following sequence 
CTCAACAGTCACTTCTTAACTGAGGCTGGCATCCATG, corresponding to nucleotides 
61- 97 in rat Il15 mRNA. The zinc finger nucleases (ZFN) contain a zinc finger protein 
with specific DNA binding and a FokI endonuclease to target DNA breaks. Following 
site-specific endonuclease activity, the target locus is disrupted and imperfect repair 
results in functional gene knockouts through frameshift deletion, in this case spanning 7 
base pairs. Il15-/- rats were created via ZFN microinjection into embryonic day (E)0.5 
rats, which were transferred into pseudopregnant rat oviducts. Germline transmission 
was achieved by backcrossing a founder Il15-/+ rat with wild-types. Il15 deficiency was 
confirmed through western blotting, without any gross morphological effects [113]. This 
model was established in order to assess the relationship between NK cells and 
placental development, and so its use in OA research is novel.  
 
1.10  Rationale, Hypothesis, Objective 
1.10.1   Rationale 
 
OA is a degenerative disorder with a clear inflammatory component and lack of a 
successful DMOAD. As such, there is a need to explore novel therapies that suppress 
the inflammatory mechanisms found in OA. The activity of cytokines is a well-defined 
area of interest in OA research, with IL-15 showing potential interest as it appears to 
play a role in increasing local catabolic activity. In order to first establish the role of IL-15 
in OA, specifically PTOA, it is beneficial to use a small animal model due to the cost 
efficiency and potential for genetic engineering. In the present study, OA was surgically 
induced in Il15-/- rats and control Il15+/+ rats to compare OA progression. 
 
1.10.2   Hypothesis 
 
Il15-/- rats will demonstrate a slower progression of PTOA compared to Il15+/+ rats. 
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1.10.3   Objectives 
 
Objective 1: Determine if Il15-/- rats have undisturbed baseline joint morphology, in order 
to make successful comparisons in the PTOA group.  
 
Objective 2: To examine the role of IL-15 in PTOA pathogenesis by comparing disease 









































2.1   Animals and Genotyping 
 
Dr. Stephen Renaud gifted Il15-/+ Holtzman Sprague-Dawley rats, which were bred in-
house. Rats were housed in a temperature- and humidity-controlled room (20-25 !, 40-
60%), with good ventilation. Water and standard rat chow was freely available. Rats 
were housed in colony cages and on a standard 12 hour light/dark cycle. All animal 
experiments were in accordance with the Canadian Council on Animal Care guidelines 
and were approved by the Animal Use Subcommittee at Western University (2019-029). 
Rats were genetically modified via ZFN [113]. The process is described in detail in 
Section 1.9.1, so briefly, the second exon of Il15 was targeted using zinc finger 
nucleases-mediated genome editing, causing a 7 base pair frameshift deletion  
(Fig 2.1.A). A founder rat with a monoallelic Il15 frameshift deletion was identified and 
backcrossed to wild type rats in order to achieve germline transmission [113]. A group 
of Il15-/+ rats were gifted to our group for this experiment and genotyped using extracted 
DNA from ear biopsies. Four primers were purchased from Sigma-Aldrich to distinguish 
the wild type and mutant rats by PCR analyses on genomic DNA (Fig 2.1.B-C). Il15+/+ 
rats were identified by a 152 bp band, Il15-/- by the 252 bp band, and therefore Il15-/+ by 
both simultaneously. Male Il15+/+ and Il15-/- rats were then randomly allocated to either a 





Figure 2.1 Genetically modified Holtzmann-Sprague Dawley rats  
Holtzmann Sprague-Dawley rats were genetically modified via zinc finger nucleases 
(ZFN) by Dr. Renaud to delete Il15 [108]. A) The second coding exon of the rat Il15 
gene was targeted via ZFN. Non-coding regions are represented with white boxes, 
coding regions with black boxes. The red box outlines the ZFN target sequence, which 
resulted in a 7-nucleotide deletion and subsequent frameshift (red text) for the Il15-/- 
rats. B - C) Four primers were used to genotype the rats through PCR. The reverse 
primer, R1704, was specific to Il15+/+ rats and produced a 152-bp band in combination 
with F1552. The forward primer, F1666, was specific to Il15-/- rats and produced a 252 
bp-band in combination with R1918. 
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2.2   Surgery 
 
Garth Blackler performed anterior cruciate ligament transection with destabilizing medial 
meniscus (ACLT-DMM) surgery on the right knees of 9.5 week old male rats, as 
described by Appleton et al. (2007) with some modifications [114]. The medial meniscus 
was destabilized by transecting the medial meniscotibial ligament instead of partially 
transecting the medial meniscus (Fig 2.2). Surgical anesthesia was induced using 5% 
Isofluorane, then decreased to 2% for maintenance. Ampicillin (40 mg/kg) was 
administered subcutaneously as a prophylactic antibiotic, and slow release 
Buprenorphine (1 mg/mL) was administered subcutaneously as a post-operative 
analgesic. Age-matched rats that did not have any kind of surgery were used as the 
controls, termed the Naive group. Weights were measured for the first 4 days post-
operatively, and then weekly. All rats were euthanized by asphyxiation with CO2 at the 8 




Figure 2.2 – Surgically-induced OA  
OA was induced through anterior cruciate ligament transection with destabilizing medial 
meniscus (ACLT-DMM) surgery in male rats. The joint capsule was opened anterior to 
the medial collateral ligament, followed by transection of the anterior cruciate ligament 





2.3   Behavioural Testing 
 
Mechanical allodynia was measured using Electronic von Frey testing (Bioseb, Vitrolles, 
France). Rats were placed in a Plexiglass box apparatus for 20 minutes of habituation. 
The plastic von Frey tip was applied to the footpad center of the rat hind paw until there 
was a pain response, at which point the threshold was electronically recorded. A painful 
response was counted as anytime the rat withdrew their paw and/or vocalized. Testing 
was done at baseline (pre-operatively), 4 weeks, and 8 weeks post-operatively.  
 
2.4   Histopathology and Scoring 
 
Right knees were dissected and fixed in 4% paraformaldehyde at 4 ! overnight. An 
initial decalcification protocol was performed on half of the samples, using Formical-
2000TM (StatLab, Baltimore, MD) on coronally bisected joints. Knees were frontally 
sectioned at 6 µm, following processing and paraffin embedding. This protocol was not 
effective, and so surface decalcification with Decal StatTM (StatLab, Baltimore, MD) was 
performed for each 100 µm of tissue. Due to the variability of surface decalcification and 
time constraints, a new decalcification protocol was utilized for the remaining samples. 
Here, Decal StatTM was used for the first 24 hours, followed by Formical-2000TM as in 
the previous protocol. Surface decalcification was not necessary for these samples. The 
centre of the joint was analyzed by staining 3-5 serial sections, 200 µm apart  
(Fig 2.3.A), stained in 0.04% Toluidine Blue for cartilage damage or with Hematoxylin 
and Eosin (H&E) for synovitis analysis. Slides were randomized and blinded for scoring 
by 2 observers.  
 
Toluidine Blue stained sections were analyzed using the Osteoarthritis Research 
Society International (OARSI) rat histopathologic system [115]. Anatomical landmarks 
were identified in order to assess section depth and designate quadrants (Fig 2.3.B). 
Cartilage degeneration, subchondral bone damage, and osteophytes were graded in 
four knee quadrants - Medial Femoral Condyle (MFC), Medial Tibial Plateau (MTP), 
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Lateral Femoral Condyle (LFC), and Lateral Tibial Plateau (LTP). As per OARSI 
guidelines, the cartilage damage is assessed across on a scale from 0 (no damage) to  
5 (severe damage). Further, the cartilage in each quadrant was assessed in 3 equal 
zones, with scores summed in order to represent the total cartilage damage for a 
maximum total of 15. Zone 1 was labelled as the area adjacent to the meniscus, Zone 2 
as the middle area, and Zone 3 being adjacent to the cruciate ligaments (Fig 2.3.C). 
Similarly, the subchondral bone damage was assessed on a scale from 0 (no damage) 
to 5 (severe damage), but was not separated into zones. Finally, osteophyte sizes were 
measured from the osteophyte base to its edge at the thickest point using ImageJ 1.52q 
by one blinded observer. A corresponding score from 0 – 4 was assigned, as per 
OARSI guidelines (Fig 2.3.D). For each animal, a score per parameter was assigned 
based on the mean, median, peak, and summed score for the slides. Within the 
summed score, there is a maximum score of 75 for total cartilage damage, 25 for 
subchondral bone damage, and 20 for osteophyte scores. 
 
H&E-stained sections were analyzed using a six parameter synovial scoring system, 
assessing synovial lining thickness, sub-synovial infiltration, fibrin deposition, 
vascularization, fibrosis, and perivascular edema [116]. Scoring was done across the 
Medial and Lateral Parapatellar, Superior, and Inferior compartments with a score of 0 
(none) to 3 (severe) for each parameter, resulting in a total of 36 scores per slide  
(6 parameters across 6 compartments). Final scores were calculated for each animal by 
calculating the mean score across the 6 compartments per parameter, with the final 
score representing the sum of the means for a maximum score of 18. For example, to 
calculate the final synovial lining thickness score for one animal, the mean score from 
the Medial Parapatellar compartment was calculated from the scored slides. This was 
then repeated for the remaining compartments. Lastly, the final score was calculated by 







Figure 2.3 – OARSI scoring methodology was used to assess OA   
Cartilage damage, subchondral bone damage, and osteophytes were assessed using 
the OARSI scoring system [115]. A) The centre of the joint was collected for scoring, 
spanning 3 – 5 slides, 200 µm apart. M = medial meniscus, L = lateral meniscus, and  
A = anterior cruciate ligament. B) Anatomical landmarks were identified in order to 
assess slide depth and locate quadrants for scoring. C) Cartilage damage was 
assessed on a scale from 0 – 5 in three equal zones, for a total cartilage damage score 
out of 15. Zones 1 was adjacent to the meniscus, Zone 2 in the middle, and Zone 3 was 
adjacent to the cruciate ligaments. D) Osteophyte size was determined by measuring 
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the osteophyte from the base to its edge at the thickest point, and then a score was 
assigned from a scale of 0 – 4. Scale bar = 200 µm.  
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2.5   Statistical Analysis 
 
Statistical analyses were performed in GraphPad Prism v.8.2 and IBM SPSS Statistics 
v.23. SPSS was used for Cohen’s kappa and Chi-Squared analysis, and Prism for any 
remaining statistics. Cohen’s kappa was run for inter-rater reliability of cartilage 
degeneration, subchondral bone damage, and synovitis scoring. The Chi-Squared test 
of independence with Cramer’s V was run between groups for the presence of 
osteophytes. Normality was assessed via the D’Agostino & Pearson test. A two-way 
analysis of variance (ANOVA) with Tukey’s multiple comparison test was run for all 
OARSI histological scoring. Synovitis scores were analyzed using a one-way ANOVA 
with Tukey’s multiple comparison test, or the Kruskal-Wallis with Dunn’s multiple 
comparison test, depending on normality. Weight was compared using a Two-Way 
ANOVA with repeated measures, and Tukey’s multiple comparison test. Finally, 
behavioural data were analyzed using a two-way ANOVA, mixed-effects model.  




















3.1   General Health and Behavioral Analysis  
 
In order to assess general health following surgery, all animals were weighed daily for 
the first 4 days post-operation (or timepoint start in the case of the Naive group), then 
weekly until the end of the 8-week timepoint. There was no significant weight difference 
between any groups at any timepoints (Fig 3.1). All groups steadily gained weight over 
time, with a mean increase of 164 g from baseline to week 8. The Il15+/+ PTOA rats 
were the only group to lose weight during the first 4 days post-op, although it was not  
significant compared to the remaining groups. The general health of all animals was 
good, with no adverse events observed following surgery or otherwise.  
 
Mechanical allodynia was measured on a small subset of animals using the Electronic 
von Frey assay at baseline, 4-, and 8-weeks, represented by paw withdrawal threshold 
in grams. Values are outlined in Fig 3.2.A. Due to the low N, this data is exploratory 
only. There was no significant difference in withdrawal thresholds in either of the Naive 
groups. Within the PTOA groups, both had a significant decrease in withdrawal 
threshold at 4-weeks post-op, demonstrating an increase in mechanical allodynia. The 
Il15+/+ PTOA group significantly changed at 8-weeks, returning to baseline levels, while 
Il15-/- PTOA rats continued to show increased allodynia, but again, this is only 
exploratory. A more robust N is required in order to make any final conclusions on 






Figure 3.1 – All groups gained weight similarly over the 8 weeks  
Weight, in grams, was measured daily for the first 4 days post-operation, and then 
weekly for 8 weeks. A Two-Way ANOVA with repeated measures, and Tukey’s multiple 
comparison was run post-hoc. There was no significant difference between the groups 
at any timepoint, with all groups steadily gaining weight throughout the experiment. (N = 
15 rats/PTOA group, and N = 9 rats/Naive group, p > 0.05, data represented are mean 





Figure 3.2 – Exploratory analyses of effects of PTOA on mechanical allodynia  
Electronic von Frey analysis was used to determine changes in mechanical allodynia at 
baseline, 4-, and 8-weeks. A) Mean paw withdrawal threshold, in grams, is shown per 
group. B) Exploratory analysis reveals that paw withdrawal threshold was significantly 
decreased from baseline to 4-weeks in both PTOA groups, but only significantly 
increased back to baseline at 8-weeks for the Il15+/+ PTOA group. Although, a greater N 
is required in order to make final conclusions. The Naive groups remained unchanged 
at all timepoints. Data represents results from a Two-Way ANOVA, mixed-effects model 
with Tukey’s multiple comparison post-hoc. (* p < 0.05, ** p < 0.01, N = 3 rats/PTOA 
group, and N = 9 rats/Naive group, data represented are mean with SD). C) Plastic von 
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Frey tip is gradually applied to the middle of the rat hindpaw (red circle) until the rat 































3.2   Control Group 
 
In order to study PTOA in the rat model, OA was surgically induced at 9.5 weeks of age 
via ACLT-DMM surgery. A sham surgery, where the joint capsule is opened but no 
further tissue transection takes place, was not performed as we did not want to induce 
any inflammation in the control group. Instead, we utilized age-matched rats that did not 
have any kind of surgery to serve as the controls, termed Naive.  
 
The Naive group was first analyzed to determine if there was any OA pathogenesis at 
that age and to find any differences at baseline (non-surgical) between the genetic 
strains. Semi-quantitative scoring of histological data demonstrates that there are no 
significant markers of OA pathogenesis within the Naive group [115, 116]. This includes 
no significant damage to the articular cartilage, subchondral bone, osteophyte 
presence/size, or synovitis. Further, the Il15+/+ and Il15-/- Naive groups did not 
significantly differ (Fig 3.3). The Naive group did have some instances of cartilage or 
subchondral bone damage in the Lateral Femoral Condyle (LFC) without any obvious 
traumatic event, for both genetic strains, which are included in the analysis and 
considered to be variations of normal (Fig 3.4). Overall, the Naive joints demonstrated 
healthy joint physiology across all 4 quadrants and in both genotypes. With the 
understanding that the Naive group successfully serves as a control, data is presented 






Figure 3.3 – Representative histological images demonstrate healthy joint tissues 
in Naive rats  
Representative images of toluidine blue-stained paraffin sections of rat knees, 
demonstrating that the Naive group had no significant differences between genotypes 
and was overall healthy. Semi-quantitative scoring demonstrates no significant damage 
to the articular cartilage, subchondral bone, and osteophyte formation. Images were 





Figure 3.4 – Sample image of tissue damage in Naive rats 
Representative image of toluidine blue-stained paraffin section of the variations of 
normal seen in the Naive group. Instances of cartilage damage with subchondral bone 
damage was evident in the Lateral Femoral Condyle (LFC) in the absence of a 
traumatic event in the Naive group. This occurred in both genetic strains and is included 
in the analysis as a variation of normal. Image taken at 4X magnification, scale bar 
represents 200 µm (N = 9 rats/Naive group).   
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3.3   Cartilage Damage after Surgery 
 
Following tissue collection at the end of timepoint, OARSI histological analysis was 
carried out by 2 scorers, using a semi-quantitative scoring system with a scale from 0 
(no damage) to 5 (severe damage) to quantify articular cartilage damage across 4 
quadrants. Further, the cartilage in each quadrant was assessed in 3 equal zones, with 
scores summed in order to represent the total cartilage damage (maximum total of 15) 
[115]. The weighted kappa score was 0.71, demonstrating substantial rater agreement, 
according to the Landis & Koch (1977) guidelines [117]. 
 
The PTOA groups had significantly higher OARSI scores compared to the Naive 
groups, which was contained to the medial part of the joint, with the highest scores in 
the MTP. However, the damage across the articular cartilage was not significantly 
different between Il15+/+ PTOA and Il15-/- PTOA rats in the mean, median, peak, and 
summed scores (Fig 3.5). Zonal analysis revealed that Zone 2 had significantly higher 
scores, although this was also non-significant when comparing Il15+/+ to Il15-/- animals. 
Articular cartilage damage was observed through the loss of GAGs, chondrocyte 
clustering, and cartilage loss, ranging from surface loss to loss of the deep zone  
(Fig 3.6). Overall, cartilage damage does not appear to be significantly different in any 





Figure 3.5 – Cartilage damage is not significantly different between Il15+/+ PTOA 
and Il15-/- PTOA animals  
Animals either underwent ACLT-DMM surgery to induce PTOA or served as control with 
no surgery (Naive). Semi-quantitative scoring (scale 0 – 5) of toluidine blue-stained 
paraffin sections was used to determine the extent of cartilage damage in the joint via 4 
compartments; medial femoral condyle (MFC), medial tibial plateau (MTP), lateral 
femoral condyle (LFC), and lateral tibial plateau (LTP). A – D) Two-Way ANOVA with 
Tukey’s multiple comparison test was run, data represents mean with 95% CI. Mean, 
median, peak, and summed scores all demonstrate that there was no significant 
difference between the Il15+/+ PTOA and Il15-/- PTOA groups. Across all scores, the 
PTOA groups scored significantly higher than the Naive groups in the medial 









Figure 3.6 – Representative high magnitude images of articular cartilage damage  
Histological images of the cartilage damage found in the PTOA animals. Chondrocyte 
clustering (red arrow), glycosaminoglycan loss through loss of staining, and cartilage 
loss is seen. The cartilage loss varies from surface fibrillations (red box) to total loss 
expanding to the tidemark. Images take at 20X magnification, scale bars represent 100 













Figure 3.7 – Representative histological images demonstrate greatest damage in 
the medial compartment of the PTOA group  
Representative images of toluidine blue-stained paraffin sections of rat knees, 
demonstrating that the PTOA group had the greatest damage in the medial aspect as 
seen by osteophytes (red arrow), cartilage loss, and subchondral bone damage (red 
arrow heads). This damage was not significant different between the Il15+/+ PTOA and 
Il15-/- PTOA rats. Images taken at 4X magnification, scale bars represent 200 µm  








3.4   Subchondral Bone and Osteophytes  
 
Subchondral bone damage was assessed similarly to the articular cartilage damage, 
with a semi-quantitative score from 0 – 5 [115]. There was almost perfect inter-rater 
agreement in this parameter, with a weighted kappa of 0.86 [117]. Only the medial tibial 
plateau demonstrated significantly higher scores in the PTOA groups compared to the 
Naive groups. The mean, median, peak, and summed scores between the Il15+/+ PTOA 
and Il15-/- PTOA rats was not significantly different in any of quadrants (Fig 3.8.A-D). 
Subchondral bone damage was observed in the PTOA groups through bone marrow 
mesenchymal changes, fragmentation of calcified cartilage, marrow chondrogenesis, 
and articular cartilage collapse (Fig 3.9).  
 
Osteophytes were analyzed by recording the presence or absence by both raters, and 
subsequently measured by one rater. The presence of osteophytes was analyzed first, 
revealing a significant relationship between groups and osteophyte presence in the 
medial compartment. Further analysis found this to be a strong association in both the 
medial femur and tibia, with the PTOA groups more likely to present with osteophytes 
(Cramer’s V = 0.64 and 0.60, respectively). In the lateral compartment, the same 
relationship was present in only the femoral condyle, with a moderate association 
(Cramer’s V = 0.43; Fig 3.10.A). Examination of the osteophyte size reveals no 
significant difference between the Il15+/+ PTOA and Il15-/- PTOA rats in the mean, 
median, peak, and summed scores (Fig 3.10.B-E). Overall, there was no significant 
difference in the severity of subchondral bone damage between the Il15+/+ PTOA and 





Figure 3.8 – Subchondral bone damage is not significantly different between 
Il15+/+ PTOA and Il15-/- PTOA rats 
Animals either underwent ACLT-DMM surgery to induce PTOA or served as a control 
with no surgery (Naive). Semi-quantitative scoring (scale 0 – 5) was used to determine 
the extent of subchondral bone damage in the joint via 4 compartments; medial femoral 
condyle (MFC), medial tibial plateau (MTP), lateral femoral condyle (LFC), and lateral 
tibial plateau (LTP). A – D) Two-Way ANOVA with Tukey’s multiple comparison test 
was run, data represents mean with 95% CI. Mean, median, peak, and summed scores 
all demonstrate that there was no significant difference between the Il15+/+ PTOA and 
Il15-/- PTOA groups. Across all scores, the PTOA groups scored significantly higher than 








Figure 3.9 – Representative image of subchondral bone damage in PTOA rats 
Histological images of the articular cartilage collapse/infiltrating into the subchondral 
bone. The collapse varies from a mild break in the tidemark, with some non-calcified 
cartilage infiltrating into the bone, to the most severe, where the cartilage has collapsed 
to a depth greater than 250 µm with increased mesenchymal changes to the bone 





Figure 3.10 – Osteophyte size is not significantly different between Il15+/+ and  
Il15-/- animals 
Animals either underwent ACLT-DMM surgery to induce PTOA or served as control with 
no surgery (Naive). Osteophytes were analyzed for absence/presence and size in the 4 
compartments; medial femoral condyle (MFC), medial tibial plateau (MTP), lateral 
femoral condyle (LFC), and lateral tibial plateau (LTP). A) Presence of osteophytes was 
determined and agreed upon by two scorers. Chi-squared analysis with Cramer’s V 
established that the PTOA groups were strongly associated with osteophyte presence in 
the medial compartment, and moderately associated in the LFC, with no significance in 
the LTP. (MFC = X2 (3, N = 45) = 18.24, p < 0.0001, Cramer’s V = 0.64, MTP = X2 (3, N 
= 45) = 16.38, p < 0.005, Cramer’s V = 0.60, LFC = X2 (6, N = 45) = 16.90, p < 0.05, 
Cramer’s V = 0.43, LTP = X2 (3, N = 45) = 7.05, p > 0.05). B – E) Two-Way ANOVA 
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with Tukey’s multiple comparison test was run, and data represents mean with 95% CI. 
Mean, median, peak, and summed scores all demonstrate that there was no significant 
difference between the Il15+/+ PTOA and Il15-/- PTOA groups. Mean, median, and peak 
represents osteophyte size, while the summed score represents the designated OARSI 
score (p > 0.05, N = 15 rats/PTOA group and 9 rats/Naive group). 
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3.5   Synovitis  
 
Synovitis was similarly assessed using a semi-quantitative 6 parameter scoring system 
[116]. A score from 0 (none) to 3 (severe) was given across 6 compartments (medial 
and lateral parapatellar, superior, and inferior compartments) for 6 parameters; (1) 
synovial lining thickness, (2) sub-synovial infiltration, (3) surface fibrin deposition, (4) 
vascularization, (5) fibrosis, and (6) perivascular edema. Preliminary inter-rater analysis 
reveals substantial to almost perfect agreement, with a weighted kappa ranging from 
0.67 to 0.85 across the six parameters (Table 3.1) [117]. There was no significant 
difference between the Il15+/+ PTOA and Il15-/- PTOA rats across all six parameters  
(Fig 3.11). When comparing the PTOA to Naive group, only the sub-synovial infiltrate 
and surface fibrin scores are significant, but again there is no difference between 
genetic strains (Fig 3.12). Overall, synovitis is not significantly different between the 
Il15+/+ PTOA and Il15-/- PTOA rats.   
 




Figure 3.11 – Synovitis is not significantly different between Il15+/+ and Il15-/- 
animals 
Rats either underwent ACLT-DMM surgery to induce PTOA or served as control with no 
surgery (Naive). Semi-quantitative scoring was used to assess synovitis across 6 
parameters, ranging from 0 (none) to 3 (severe), measured in 6 zones (medial and 
lateral parapatellar, superior, and inferior compartments). A One-Way ANOVA with 
Tukey’s multiple comparison test or the Kruskal-Wallis with Dunn’s multiple comparison 
test was run, depending on normality. Data represents mean with 95% CI. Analysis 
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reveals that the PTOA group had scored significantly higher for sub-synovial infiltration 
and surface fibrin, although there was no significant difference between genetic strains. 
The remaining 4 parameters were non-significant across all groups (* p < 0.05, N = 15 





Figure 3.12 – Representative images of synovitis in the PTOA group  
Histological images of the synovitis, as demonstrated by surface fibrin and sub-synovial 
infiltration, found in the PTOA animals. Healthy synovium (first box) is presented as a 
comparison and represents Naive tissue. Surface fibrin (red arrow) and sub-synovial 
infiltration (red arrowheads) was found significantly more in the PTOA group compared 
to the Naive, but was not different between genetic variants. Images take at 20X 
magnification, scale bars represent 100 µm (N = 15 rats/PTOA group and N = 9 




















Cytokine activity is a well-defined research area in OA, offering many potential 
therapeutic targets to be explored. Interleukin-15 (IL-15), a pro-inflammatory cytokine, 
has been shown to have increased levels in OA and can potentially increase catabolic 
activity within the joint. Our study utilized a Holtzmann Sprague-Dawley male global 
Il15-/- model to study the roles of IL-15 in PTOA progression. Our work demonstrated 
that Il15-/- rats present with normal joint morphology and display similar PTOA 
progression as their Il15+/+ counterparts. Through the analysis of cartilage damage, 
subchondral bone damage, osteophyte formation, exploratory behavioural data, and 
synovitis we did not see any significant differences between genotypes, suggesting that 
IL-15 does not play a vital role in PTOA progression in this rat model. These data do not 
support our initial hypothesis.  
 
The use of Il15-/- rats in OA research is novel, and so we first had to establish that 
mutant rats have normal joint morphology in the absence of surgery. The whole-body 
(global) Il15 knockout was generated by Renaud and colleagues (2017) and confirmed 
through western blotting [113]. They did not observe gross morphological defects, but 
the model was created to examine placental development, and so joint health was not 
studied. The Naive group, which did not undergo PTOA-inducing surgery, was 
examined first. Our results did not find any evidence of disturbed joint morphology in the 
Il15-/- rats across all parameters, compared to the Il15+/+. This includes no statistically 
significant evidence for pain sensitization, cartilage damage, subchondral bone 
damage, osteophyte formation and size, and synovitis. Overall, the Il15-/- rats had 
healthy knee joints that were comparable to the Il15+/+ rats in all ways. Interestingly, 
there was some instances of disturbed subchondral bone without obvious trauma in the 
Naive group, but this occurred in both genetic strains. This damage was generally 
observed in the LFC, which was minimally damaged in the PTOA groups. As this was 
observed equally in both Il15-/- and Il15+/+ rats without a clear triggering event, the data 
was included in the analysis as a variation of normal. Indeed, these variations did not 
result in any significant differences when analyzing the subchondral bone.  
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Weight was recorded as a measure of general health, especially for the PTOA group 
following surgery. There was no significant difference in weight at any timepoint 
between all groups, similar to the findings from Renaud et al. (2017) with their female 
rats [113]. Even though the Il15+/+ PTOA rats lost weight during the first 4 days post-op, 
this loss was not significant, and they continued to gain weight in the weeks following. 
Interestingly, the Il15-/- rats, in both the PTOA and Naive groups, consistently weighed 
less than their Il15+/+ counterparts, although not enough to reach statistical significance. 
Il15-/- mice have varied in their reported weight differences in the literature, for example 
Kennedy et al. (2000) reported that Il15-/- mice were not significantly different in body 
weight compared to Il15+/+ mice, but another study reported their male Il15-/- mice 
weighed less [118, 119]. Similarly, the mouse model of Il15R𝛼-/- (IL-15 receptor alpha 
deficient mice) has conflicting reports of weight, either reporting similar weights or a 
decrease in weight in mutants compared to controls [120, 121]. Interestingly, Il15-/- mice 
on a high fat diet are resistant to diet-induced weight gain due to increased thermogenic 
capacity in brown and beige fat cells [122]. Our male Il15-/- rats appear to trend towards 
weighing less, perhaps due to a similar increased thermogenic capacity, although not 
enough to reach statistical significance. Another explanation could be the importance of 
IL-15 signaling in bone turnover, as IL-15 signaling is critical for osteoblast/osteoclast 
coupling and the mineralization capacity of osteoblasts, as seen in Il15R𝛼-/- mice [104]. 
Perhaps the decrease in bone mineralization contributed to the weight loss trend in our 
Il15-/- rats.  
 
In order to assess PTOA progression, surgery to transect the anterior cruciate ligament 
and destabilize the medial meniscus (ACLT-DMM) was utilized in both Il15-/- and Il15+/+ 
rats. Collection at the 8-week timepoint after surgery revealed that the surgery 
successfully induced PTOA, as this group had statistically higher scores for cartilage 
damage, subchondral bone damage, and osteophyte presence compared to the Naive 
group. As expected, the damage was generally contained to the more weight bearing 
medial compartment. There is also evidence of synovitis developing in the PTOA group, 
as they scored significantly higher for sub-synovial infiltration and surface fibrin 
deposition, compared to the Naive group. Further, behavioural data found an increase 
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in pain sensitivity in the PTOA groups, although this is exploratory (N = 3 rats/PTOA 
group, N = 9 rats/Naive group). Our exploratory data followed the expected pattern, 
where pain sensitization was greatest around 4 weeks, and then slightly declined and 
plateaued [123]. The Il15+/+ rats had a significant reduction in pain sensitization from 4- 
to 8-weeks, but the Il15-/- rats did not, but further data including a much larger N is 
required in order to make any conclusions.  
 
Synovitis, as measured through 6 parameters, was observed in the PTOA group 
through sub-synovial infiltration and surface fibrin deposition. Previous studies from the 
Appleton lab demonstrated synovial hyperplasia at 4-weeks and surface fibrin at both 4- 
and 12-week timepoints, although there was no data for 8-weeks (unpublished). Our 
data follows the expected pattern, where surface fibrin continues to be present at all 
timepoints. Additionally, the sub-synovial infiltration we found follows the expected 
trend, as this parameter was increased at 4-weeks and then decreased by 12-weeks, 
although not significantly. Taken together, these data suggest sub-synovial infiltration 
begins increasing as early as 4-weeks, reaches significant levels by 8-weeks, and then 
decreases at 12-weeks. Overall, ACLT-DMM surgery successfully induced mid-stage 
PTOA.   
 
Inconsistent with our hypothesis, there was no significant difference between the Il15-/- 
and Il15+/+ PTOA rats, indicating that IL-15 may not play a vital role in rat PTOA 
pathophysiology. This finding is also inconsistent with previous studies that found a 
relationship between IL-15 activity and OA, which may be due to a few factors. Firstly, it 
is possible that the rodent model is not ideal for translating studies in IL-15, as current 
literature on IL-15 and OA has exclusively been reported from human studies [108-112].  
This is one of the limitations with small animal research, although the cost-effective and 
ease of use provides an excellent opportunity to explore therapeutic targets. As such, 
while there could be translational issues between the studies, other limiting factors 
should be considered first. For example, our study examined only the 8-week timepoint, 
but the activity of IL-15 may be more robust at an earlier or later stage of disease. Work 
by Scanzello et al. (2009), comparing early and late stage IL-15 levels, would suggest 
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that IL-15 is more active during the early stage of disease [109]. Comparatively, studies 
measuring IL-15 levels in OA patients tend to utilize patients at the end stage of the 
disease, due to the convenience of tissue collection during arthroplastic surgery. 
Elevated levels of IL-15 in these patients could suggest that it continues to play a role 
even at the end-stage of disease [108, 112]. Our model could benefit from the addition 
of early and late stage PTOA in order to further explore this relationship.  
 
Another pitfall could be due to differing OA phenotypes. The current literature examining 
IL-15 and OA has excluded patients with a history of traumatic joint injury, thus 
excluding PTOA, which could be another reason for the lack of significance between 
groups [108-112]. IL-15 may play a more vital role in other OA phenotypes, such as 
primary OA, as seen in human studies, or potentially in metabolic OA. Research utilizing 
Il15-/- mice on a high fat diet revealed an important role for IL-15 in metabolic syndrome, 
as it seems to promote chronic inflammation in adipose tissue [122]. Perhaps the 
inflammatory role of IL-15 is more substantial in metabolic OA than in PTOA. Finally, the 
redundant and pleiotropic nature of cytokines could explain why the absence of IL-15 
did not cause a change in PTOA progression. This is partly due to the ability to signal 
through multiple receptor complexes and shared receptors; for example, IL-15 has a 
shared 𝛽 receptor with IL-2 and a common 𝛾 receptor, shared by 5 interleukins [102, 
124]. This redundant nature may be a reason that therapy singularly targeting IL-1𝛽 or 
TNF𝛼 has not been effective, and significant slowing of OA progression could require a 
combination therapy [125]. Additionally, the activity of IL-15 on catabolic factors, like 
MMPs, may be more indirect, as suggested by recent work by Warner and colleagues 
(2020). Chondrocytes treated with IL-15 in vitro demonstrate a delayed release of  
MMP-1 and -3, compared to TNF𝛼, which may point to an indirect effect of IL-15 on 
these MMPs [110]. Therefore, the action of IL-15 to increase catabolic activity in the 
joint may be taken over by another cytokine when IL-15 is absent, especially if this 







Limitations and Future Directions  
 
It is important to consider the limitations involved in this thesis. Many of these limitations 
were due to the laboratory shutdown during the COVID-19 pandemic, which intervened 
with completion of additional in vivo experiments. Within our study, the behavioural data 
is exploratory due to the small N in the PTOA group. While our work did follow the 
expected pattern of pain sensitivity following surgery, it is not clear whether there are 
significant differences between the groups and genotypes. Further, we only analyzed 
one pain measure, which while helpful, does not encompass the multifaceted nature of 
OA pain. Future work should include further pain measures, such as mechanical 
analgesia or thermal hyperalgesia. Our work also lacked immunohistochemistry (IHC) or 
other molecular data, although there was an attempt to demonstrate IL-15 presence in 
the joint through IHC. Since IL-15 is mandatory for NK cell maturation, we targeted 
perforin, a pore-forming protein found in NK cells, as a surrogate marker for IL-15 
activity. Unfortunately, this is a non-specific antibody whose target is also found in  
T-lymphocytes, so we were unable to obtain convincing data to effectively compare 
 IL-15 activity. Future work would benefit from an optimized method of IL-15 detection in 
the joint in order to assess the expression of IL-15 in the rodent joint. As previously 
discussed, focusing on one timepoint and one OA phenotype only could also be a 
limitation, and so studies involving multiple timepoints and perhaps a metabolic or aging 
OA model could be beneficial to exploring the role of IL-15 in OA.  
 
Other limitations include the use of a global (whole-body) knockout rodent model, which 
limits our confidence in the effects of IL-15 on the joint. As it is widely expressed, there 
could have been off target effects or compensatory events that interfered with our study. 
This could be solved by utilizing tissue-specific Cre drivers to target only the cartilage or 
subchondral bone, although these approaches are much less established in rats than in 
mice. Additionally, our work only examined male rats, although sex-related differences 
are possible. In fact, OA incidence, progression, and severity are higher in post-
menopausal females, demonstrating that sex hormones could be chondroprotective pre-
menopause [126]. In addition, male mice develop more severe surgically-induced OA 
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compared to females [127]. It would therefore be beneficial to examine Il15-/- female rats 
as well to explore any sex-related differences.  
 
Further, the use of a solely in vivo model limits the scope of our work in understanding 
the mechanisms of IL-15 in a more complex manner. An in vitro model studying primary 
rat or human synoviocytes that are treated with IL-15 would be an interesting study, 
demonstrating the effects and mechanism of IL-15 in the synovium. Finally, our  
ACLT-DMM model is invasive and does not perfectly mimic the real world injuries 
associated with PTOA. In our model, the joint capsule must first be transected in order 
to access the ACL and meniscus, which would normally remain undisturbed during joint 
trauma. In order to successfully transect both structures some blood has to be cleared, 
although every attempt is made to clear as little as possible and suture the joint capsule 
closed with the blood present. This is done in order to minimize any unintended effects 
on the progression of PTOA, although there may still be some effect. Future work could 
utilize a non-invasive model, where the ACL is ruptured via tibial compression in order 
to induce PTOA [128, 129].   
 
Overall, while our work did not demonstrate a significant difference in IL-15 and PTOA, 
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